Key regions: United Kingdom, Germany, France, South Korea, Italy
The COVID-19 pandemic has brought about a significant increase in demand for vaccines worldwide. Uzbekistan, a country in Central Asia, is no exception to this trend.
Customer preferences: In Uzbekistan, there is a strong preference for vaccines that are affordable and easily accessible. Due to the limited healthcare infrastructure in the country, many citizens rely on government-funded healthcare services. As a result, there is a high demand for vaccines that are provided free of charge or at a low cost. Additionally, many citizens prefer vaccines that have been approved by reputable international organizations such as the World Health Organization (WHO).
Trends in the market: Uzbekistan has been actively working to secure COVID-19 vaccines for its citizens. The government has signed agreements with several vaccine manufacturers, including China's Sinovac and Russia's Sputnik V. As a result, the country has been able to roll out its vaccination program relatively quickly. However, the pace of vaccination has been slower compared to other countries in the region. This can be attributed to a lack of vaccine hesitancy among the population, as well as logistical challenges in distributing the vaccines to remote areas of the country.
Local special circumstances: Uzbekistan has a large rural population, which presents unique challenges in terms of vaccine distribution. Many citizens in rural areas do not have access to healthcare facilities and may have limited knowledge about the importance of vaccination. To address this issue, the government has launched an awareness campaign to educate citizens about the benefits of vaccination. Additionally, mobile vaccination teams have been deployed to remote areas to provide vaccines to those who cannot travel to vaccination centers.
Underlying macroeconomic factors: Uzbekistan's economy has been heavily impacted by the COVID-19 pandemic. The country's GDP contracted by 2% in 2020, and the government has implemented several measures to mitigate the economic impact of the pandemic. This includes providing financial support to businesses and households, as well as investing in healthcare infrastructure. The government's efforts to secure COVID-19 vaccines can be seen as part of a larger strategy to promote economic recovery by controlling the spread of the virus and allowing businesses to reopen safely.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
